Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2

被引:138
作者
Linares, Laetitia K.
Kiernan, Rosemary
Triboulet, Robinson
Chable-Bessia, Christine
Latreille, Daniel
Cuvier, Olivier
Lacroix, Matthieu
Le Cam, Laurent
Coux, Olivier [1 ]
Benkirane, Monsef
机构
[1] UNII, Ctr Rech Biochim Macromol, CNRS, UMR5237, Montpellier, France
[2] CNRS, UPR1142, Mol Virol Lab, Inst Genet Humaine, Montpellier, France
[3] CNRS, UPR1142, Lab Dynam Genome & Dev, Inst Genet Humaine, Montpellier, France
[4] UNII, Inst Genet Mol Montpellier, CNRS, UMR5535, Montpellier, France
关键词
D O I
10.1038/ncb1545
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The p300-CBP-associated factor ( PCAF) is a histone acetyltransferase ( HAT) involved in the reversible acetylation of various transcriptional regulators(1), including the tumour suppressor p53. It is implicated in many cellular processes, such as transcription, differentiation, proliferation and apoptosis. We observed that knockdown of PCAF expression in HeLa or U2OS cell lines induces stabilization of the oncoprotein Hdm2, a RING finger E3 ligase primarily known for its role in controlling p53 stability(2,3). To investigate the molecular basis of this effect, we examined whether PCAF is involved in Hdm2 ubiquitination. Here, we show that PCAF, in addition to its acetyltransferase activity, possesses an intrinsic ubiquitination activity that is critical for controlling Hdm2 expression levels, and thus p53 functions. Our data highlight a regulatory crosstalk between PCAF and Hdm2 activities, which is likely to have a central role in the subtle control of p53 activity after DNA damage.
引用
收藏
页码:331 / U153
页数:14
相关论文
共 31 条
[1]   Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases [J].
Barlev, NA ;
Liu, L ;
Chehab, NH ;
Mansfield, K ;
Harris, KG ;
Halazonetis, TD ;
Berger, SL .
MOLECULAR CELL, 2001, 8 (06) :1243-1254
[2]   Post-translational modification of p53 in tumorigenesis [J].
Bode, AM ;
Dong, ZG .
NATURE REVIEWS CANCER, 2004, 4 (10) :793-805
[3]   MDM2 is a central node in the p53 pathway: 12 years and counting [J].
Bond, GL ;
Hu, WW ;
Levine, AJ .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8
[4]   Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF [J].
Brès, V ;
Tagami, H ;
Péloponèse, JM ;
Loret, E ;
Jeang, KT ;
Nakatani, Y ;
Emiliani, S ;
Benkirane, M ;
Kiernan, RE .
EMBO JOURNAL, 2002, 21 (24) :6811-6819
[5]   p53 ubiquitination: Mdm2 and beyond [J].
Brooks, CL ;
Gu, W .
MOLECULAR CELL, 2006, 21 (03) :307-315
[6]   Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability [J].
Caron, C ;
Boyault, C ;
Khochbin, S .
BIOESSAYS, 2005, 27 (04) :408-415
[7]   Identification of a multicopy chromatin boundary element at the borders of silenced chromosomal domains [J].
Cuvier, O ;
Hart, CM ;
Käs, E ;
Laemmli, UK .
CHROMOSOMA, 2002, 110 (08) :519-531
[8]   Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 [J].
Fang, SY ;
Jensen, JP ;
Ludwig, RL ;
Vousden, KH ;
Weissman, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8945-8951
[9]   Polyubiquitination of p53 by a ubiquitin ligase activity of p300 [J].
Grossman, SR ;
Deato, ME ;
Brignone, C ;
Chan, HM ;
Kung, AL ;
Tagami, H ;
Nakatani, Y ;
Livingston, DM .
SCIENCE, 2003, 300 (5617) :342-344
[10]   Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells [J].
Hengstermann, A ;
Linares, LK ;
Ciechanover, A ;
Whitaker, NJ ;
Scheffner, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (03) :1218-+